Department of Clinical and Biological Sciences, School of Specialization of Clinical Pathology, University of Turin, 10124 Turin, Italy.
Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit, San Giovanni Bosco Hub Hospital, University of Turin, 10124 Turin, Italy.
Int J Mol Sci. 2023 Feb 3;24(3):3041. doi: 10.3390/ijms24033041.
Urinary and serological markers play an essential role in the diagnostic process of autoimmune diseases. However, to date, specific and reliable biomarkers for diagnosing Behçet's disease (BD) are still lacking, negatively affecting the management of these patients. To analyze the currently available literature on serological and urinary BD biomarkers investigated in the last 25 years, we performed a systematic literature review using the Population, Intervention, Comparison, and Outcomes (PICO) strategy. One hundred eleven studies met the eligibility criteria (6301 BD patients, 5163 controls). Most of them were retrospective, while five (5%) were prospective. One hundred ten studies (99%) investigated serological biomarkers and only two (2%) focused on urinary biomarkers. One hundred three studies (93%) explored the diagnostic potential of the biomolecules, whereas sixty-two (56%) tested their effect on disease activity monitoring. Most articles reported an increase in inflammatory markers and pro-oxidant molecules, with a decrease in antioxidants. Promising results have been shown by the omics sciences, offering a more holistic approach. Despite the vast number of investigated markers, existing evidence indicates a persistent gap in BD diagnostic/prognostic indices. While new steps have been taken in the direction of pathogenesis and disease monitoring, international efforts for the search of a diagnostic marker for BD are still needed.
尿和血清标志物在自身免疫性疾病的诊断过程中起着至关重要的作用。然而,迄今为止,用于诊断贝赫切特病 (BD) 的特异性和可靠生物标志物仍缺乏,这对这些患者的管理产生了负面影响。为了分析过去 25 年来研究的 BD 的血清学和尿生物标志物的现有文献,我们使用人群、干预、比较和结局 (PICO) 策略进行了系统的文献回顾。有 111 项研究符合入选标准 (6301 例 BD 患者,5163 例对照)。其中大多数为回顾性研究,而前瞻性研究仅 5 项 (5%)。110 项研究 (99%) 探讨了血清生物标志物,只有 2 项 (2%) 关注尿生物标志物。103 项研究 (93%) 探索了生物分子的诊断潜力,而 62 项研究 (56%) 则测试了它们对疾病活动监测的影响。大多数文章报道了炎症标志物和促氧化剂分子的增加,抗氧化剂的减少。组学科学提供了更全面的方法,显示出了有前景的结果。尽管已经研究了大量的标志物,但现有证据表明,BD 的诊断/预后指标仍存在明显差距。虽然在发病机制和疾病监测方面已经采取了新的措施,但仍需要国际社会努力寻找 BD 的诊断标志物。